➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
AstraZeneca
Mallinckrodt
Merck
Dow
Boehringer Ingelheim

Last Updated: July 27, 2021

DrugPatentWatch Database Preview

Details for Patent: 8,618,160


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,618,160 protect, and when does it expire?

Patent 8,618,160 protects QBREXZA and is included in one NDA.

This patent has eight patent family members in six countries.

Summary for Patent: 8,618,160
Title:Topical glycopyrrolate formulations
Abstract: Individually packaged topical formulations comprising about 0.25 to about 6% w/w of glycopyrrolate for the treatment of hyperhidrosis, wherein said wipe is contained within a pouch resistant to leakage. The formulations may further comprise ethanol, a buffering agent and water. In addition, the formulations may further comprise a polymer system comprising a hydrophobic polymer in combination with a hydrophilic polymer.
Inventor(s): Johnston; Michael (Rowville, AU), Houlden; Robert James (Rowville, AU)
Assignee: Rose U (Palo Alto, CA)
Application Number:12/738,168
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,618,160
Patent Claim Types:
see list of patent claims
Use; Compound; Dosage form;

Drugs Protected by US Patent 8,618,160

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Journey QBREXZA glycopyrronium tosylate CLOTH;TOPICAL 210361-001 Jun 28, 2018 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y TOPICAL TREATMENT OF PRIMARY AXILLARY HYPERHIDROSIS IN ADULTS AND PEDIATRIC PATIENTS 9 YEARS OF AGE AND OLDER ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,618,160

PCT Information
PCT FiledOctober 17, 2008PCT Application Number:PCT/US2008/011907
PCT Publication Date:April 23, 2009PCT Publication Number: WO2009/051818

International Family Members for US Patent 8,618,160

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2008314628 ⤷  Try it Free
Australia 2014203072 ⤷  Try it Free
Canada 2702830 ⤷  Try it Free
European Patent Office 2200550 ⤷  Try it Free
European Patent Office 3415127 ⤷  Try it Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Merck
McKinsey
Express Scripts
Harvard Business School
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.